Insights & news

French Competition Authority Publishes Report on Distribution of Medicines and on Laboratory Testing

  • 08/04/2019
  • Articles

On 4 April 2019, the French competition authority published a voluminous sector report on the distribution of medicines and on laboratory testing (the “Report” - see attached). The Report is the result of an inquiry which started in November 2017 (see, Van Bael & Bellis Life Sciences Newsflash of 21 November 2017) and which was also the subject of public consultations in October 2018 (see, Van Bael & Bellis Life Sciences Newsflash of 18 0ctober 2018).
 
The Report contains a series of regulatory recommendations which the competition authority says will help pharmacists to become more competitive while continuing to observe their public service obligations in the interest of public health. The Report thus advocates the following measures: 

  • Loosening the rules governing online sales by (i) allowing pharmacies more leeway in having storage facilities further removed from the pharmacy; (ii) allowing pharmacists to pool their online activities by relying on a common website; and (iii) changing the financial thresholds for recruiting assistant pharmacists by no longer considering for that purpose sales of non-medicine products;
  • Taking additional measures to stimulate take-off of relatively recent public service tasks such as involvement in vaccination campaigns; fostering patient treatment adherence; and the development of telemedicine services;
  • Considering new public service tasks such as tracking non-communicable diseases or administering specific medicines under narrow conditions;
  • Relaxing the advertising rules for cosmetics and other non-medicine products as well for the pharmacy business as such;
  • Increasing the pharmacy’s access to capital;
  • Allowing specific non-medicine products (such as in vitro diagnostic medical devices) to be sold outside pharmacies – it is unclear how this proposed measure will help pharmacies.

The Report also invites the government to reconsider the income of the wholesalers-distributors which live on small margins (often smaller than those of pharmacies that buy medicines directly from suppliers) while having to cope with public service obligations.

Attachments:

Key contacts

Related practice areas

Related insights

Sign up for updates
    • 25/04/2019
    • Articles

    Spanish Competition Authority Raids Pharmaceutical Firm over Suspicions of Abusive Market Behaviour in Relation to Autoimmune Medicine

    The Comisión Nacional de Los Mercados y La Competencia, the Spanish competition authority (“CNMC”), announced today that, earlier this week, it carried out a dawn raid at the premises of an unidentified pharmaceutical firm (see, attached press release). The targeted firm is thought to have abused its dominant position in one or more markets involving the treatment of various unspecified autoimmune diseases. The CNMC suspects that the firm pursued an exclusionary commercial strategy in its dealings with health services (“Servicios de Salud”) and hospitals. The CNMC points out that the medicine at issue went off-patent and that any attempt to corner a market that is supposed to be free following the expiry of relevant patents amounts to a very serious infringement of the competition rules.

    Read more
    • 23/04/2019
    • Articles

    European Parliament Approves Manufacturing Waiver and Reduces Scope of SPC-Based Patent Rights in Medicines

    On 17 April 2019, the European Parliament (“EP”) approved a modification to Regulation No. 469/2009 which governs the supplementary protection certificate (“SPC”) for medicinal products. The modification creates a “manufacturing waiver” that encroaches on the operation of the SPC which, broadly, extends the patent protection afforded to active substances of medicines. The modification will allow EU-based companies to manufacture a generic or biosimilar version of an SPC-protected medicine during the term of the certificate, for the double purpose of either exporting to a non-EU market where protection has expired or never existed, or stockpiling the medicine during the final 6 months of SPC protection ahead of entry on the EU market once the SPC has lapsed. The “stockpiling” exception goes beyond the proposal which the European Commission initially tabled in May 2018 (see, Van Bael & Bellis Life Sciences Newsflash of 28 May 2018) and did not form part of the text which the Member States determined as their negotiating position in January 2019 (see, Van Bael & Bellis Life Sciences Newsflash of 21 January 2019). Still, the Council of the European Union is now expected to endorse the text adopted by the EP following a political agreement reached among the EU institutions in February 2019. Once published in the Official Journal of the EU, the modification to Regulation No. 469/2009 will enter into force 20 days later and will become directly applicable in all EU Member States. However, the full effects of the SPC waiver will only kick in 3 years after the date of that entry into force, currently expected to be around 1 July 2022. The creation of a manufacturing waiver is regarded as a major victory for the generic and biosimilar industries. Conversely, EFPIA, the European association of innovative pharmaceutical companies, has labelled the move as a “negative signal to the world that Europe is devaluing its intellectual property framework”. EFPIA therefore hopes that the next European Commission, which will take office following the European elections to be held between 23 and 26 May 2019, will “redress the balance, supporting research, development and innovation more broadly” (EFPIA press release of 17 April 2019).

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *